[ FDA DRUG SHORTAGES TRACKER ]

A drug shortage is a quality failure with a body count.

Live FDA drug shortage data (openFDA), grouped by status, availability, and therapeutic area. The FDA’s own root-cause analysis puts manufacturing and quality problems at the centre of the shortage crisis — which is why SPEQ treats the shortage list as a quality-system signal, not just a supply-chain one.

1,000
Active shortages tracked
852
Current
147
To be discontinued
212
Flagged unavailable
21% flagged unavailable · latest update 2026-07-30 · source: openFDA drug/shortages
NEW SHORTAGES POSTED · MONTHLY

By initial FDA posting date. openFDA lists active shortages, so older cohorts thin as entries resolve.

ACTIVE SHORTAGES BY THERAPEUTIC CATEGORY · TOP 10
WHY THIS SITS UNDER QUALITY, NOT LOGISTICS

The FDA’s 2019 report Drug Shortages: Root Causes and Potential Solutions found the dominant drivers are not scarcity of raw materials but a lack of incentives to produce, and manufacturing/quality problems that force production to stop. Mature quality systems — the difference a QMM assessment measures — are what keep a line running.

The economics of quality →FDA QMM framework →
Reset
1,178 matching shortages
DrugCompanyTherapeutic areaAvailabilityStatusPosted
Dacomitinib TabletTabletPfizer Inc.Oncology—To Be Discontinued2026-06-08
Liraglutide InjectionInjectionNovo Nordisk, Inc.Endocrinology/MetabolismAvailableCurrent2023-07-18
Dacomitinib TabletTabletPfizer Inc.Oncology—To Be Discontinued2026-06-08
Leflunomide TabletTabletSanofi-Aventis U.S. LLCRheumatology—To Be Discontinued2026-06-08
Liraglutide InjectionInjectionNovo Nordisk, Inc.Endocrinology/MetabolismLimitedCurrent2023-07-18
Liraglutide InjectionInjectionNovo Nordisk, Inc.Endocrinology/MetabolismAvailableCurrent2023-07-18
Liraglutide InjectionInjectionNovo Nordisk, Inc.Endocrinology/MetabolismLimitedCurrent2023-07-18
Leflunomide TabletTabletSanofi-Aventis U.S. LLCRheumatology—To Be Discontinued2026-06-08
Leflunomide TabletTabletSanofi-Aventis U.S. LLCRheumatology—To Be Discontinued2026-06-08
Leflunomide TabletTabletSanofi-Aventis U.S. LLCRheumatology—To Be Discontinued2026-06-08
Leflunomide TabletTabletSanofi-Aventis U.S. LLCRheumatology—To Be Discontinued2026-06-08
Dacomitinib TabletTabletPfizer Inc.Oncology—To Be Discontinued2026-06-08
Dexmedetomidine Hydrochloride InjectionInjectionSlayback PharmaAnesthesia—To Be Discontinued2026-06-05
Semaglutide TabletTabletNovo Nordisk, Inc.Endocrinology/Metabolism—To Be Discontinued2026-06-04
Semaglutide TabletTabletNovo Nordisk, Inc.Endocrinology/Metabolism—To Be Discontinued2026-06-04
Semaglutide TabletTabletNovo Nordisk, Inc.Endocrinology/Metabolism—To Be Discontinued2026-06-04
Flurazepam Hydrochloride CapsuleCapsuleRising Pharma Holdings, Inc.NeurologyUnavailableCurrent2022-08-03
Flurazepam Hydrochloride CapsuleCapsuleRising Pharma Holdings, Inc.NeurologyUnavailableCurrent2022-08-03
Albuterol Sulfate SolutionSolutionRising Pharma Holdings, Inc.PediatricAvailableCurrent2022-10-25
Clonazepam TabletTabletAurobindo Pharma USANeurologyAvailableCurrent2023-03-10
Clonazepam TabletTabletAurobindo Pharma USANeurologyAvailableCurrent2023-03-10
Quinapril/Hydrochlorothiazide TabletTabletAurobindo Pharma USACardiovascularUnavailableCurrent2023-01-19
Clonazepam TabletTabletAurobindo Pharma USANeurologyAvailableCurrent2023-03-10
Quinapril Hydrochloride TabletTabletAurobindo Pharma USACardiovascularUnavailableCurrent2023-01-19
Clonazepam TabletTabletAurobindo Pharma USANeurologyAvailableCurrent2023-03-10
Page 35 of 48
← PrevNext →

Data: U.S. FDA openFDA drug/shortages API, which lists activeshortages (Current or To Be Discontinued) — it carries no per-record cause field, so SPEQ makes no root-cause claim on individual drugs; the quality framing above is cited FDA context. openFDA publishes shortage data for drugs only; SPEQ’s cross-industry coverage lives in the recall Explorer(drug, device & food).